



V Corso Aggiornamento Ame in Endocrinologia Clinica

**NET pancreatici:
Diagnosi e stadiazione
Algoritmo terapeutico**


Dottor Nicola Fazio

AGRIGENTO

**20/22
MARZO
2014**

20 marzo Museo Archeologico di Agrigento
21-22 marzo Hotel Baglio della Luna

Neoplasie neuroendocrine pancreatiche (pNEN)



Ki-67 < 20%


WHO 2010

Ki-67 > 20%

**Tumori
neuroendocrini
pancreatici
(pNET)**

**Carcinomi
neuroendocrini
pancreatici
(pNEC)**





GEP NET: analoghi SS → raccomandazioni ENETS

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

Oberg, Ann Oncol 2004

Absolute indications

- Patients with syndrome
- Patients without syndrome with **progressing** disease


GEP NET: analoghi SS → Approvazione AIFA

AIFA nota 40

sindrome associata a tumori neuroendocrini

AIFA off-label

**Trattamento di tumori neuroendocrini in
fase evolutiva in pazienti non sindromici**



Mediana di PD = 10 mesi dalla diagnosi

**Aumento del rischio di PD del 2% per ogni
unità in più di Ki67**


Panzuto et al., JCO 2011



CLARINET trial

Lanreotide autogel vs. placebo

204 enteropancreatic NET pts



Rusznieski, ECC-2013 Amsterdam



Characteristics	CLARINET trial
N. of pts	204
Mean age	63
NET origin (treatment arm)	Pancreas 42 (42%) Midgut 33 (33%) Hindgut 11 (11%) Others 15 (15%)
Treatment naive	81%
Baseline PD	4 %



pNET
(70-80%)

pNEC
(20-30%)



**Analoghi
della SS**

Everolimus

Chemio

PRRT

**Terapie
locoregionali**


Studi clinici

**Platino/
Etoposide**

pNET: prognosis

Metastatic Neuroendocrine Tumors: Survival by Tumor Subtype

Single Institution Database (N=937)



Pancreatic NET 5.9 yrs

Small Bowel Carcinoid: 10.1 years

Ter-Minassian et al, Endocrine Related Cancer 2013; 20: 187-96

SEER Database

Site	Median Survival (months)		
	Localized	Regional	Distant
Appendix	>360	>360	27
Cecum	135	107	41
Colon	261	36	5
Duodenum	107	101	57
Gastric	154	71	13
Liver	50	14	12
Lung	227	154	16
Pancreas	136	77	24
Rectum	290	90	22
Small bowel	111	105	56
Thymus	110	68	40

Pancreatic NET 2 years

Small Bowel Carcinoid: 4.6 years

Yao JC et al. J Clin Oncol. 2008;26:3063-3072



NEN: guidelines




Dal 2013





NENs: therapies evolution





Impostazione terapeutica

Diagnosi certa



NET “puro”

**MANEC = mixed adeno-neuroendocrine
carcinoma**



Impostazione terapeutica

Diagnosi certa



NET “puro”

**Inquadramento
clinico paziente**




P.S., sindrome

**Caratterizzazione
malattia**




pNEN: caratterizzazione di malattia

Morfologia



Ki-67





FDG



SSTR

Octreoscan® PET-TC Ga⁶⁸-DOTA



Evolutività radiologica

TC trifasica





Tumore neuroendocrino del pancreas

Caratteristiche del tumore

**PET-Ga
+++**


Ben diff.

Ki67 2%

**TC o RM dopo 2 -3 mesi : SD
o lieve PD**

Caratteristiche del paziente


Asintomatico, P.S. 0



SSA



pNEN: le due categorie estreme





Impostazione terapeutica

Diagnosi certa



NET “puro”


**Inquadramento
clinico paziente**



P.S., sindrome

**Caratterizzazione
malattia**

**Obiettivi immediati e
tardivi**



**Strategia
terapeutica**



Grazie !